Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Blood Adv. 2018 Nov 27;2(22):3193-3195. doi: 10.1182/bloodadvances.2018027078.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Anticoagulants
  • Atrial Fibrillation*
  • Factor Xa Inhibitors
  • Humans
  • Stroke*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors